BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respiratory tract infection. METHODS:Infants hospitalized with lower respiratory tract infection and a positive RSV test performed locally were randomized to receive 1 intravenous dose of motavizumab (30 or 100 mg/kg) or placebo. Nasal wash samples were tested by real-time reverse transcriptase polymerase chain reaction at a central laboratory to determine viral load. Clinical data were collected during RSV hospitalization and at 12-month follow up. RESULTS: Of 118 infants, 112 were confirmedRSV positive by real-time reverse transcriptase polymerase chain reaction. In each study group, median (range) RSV load (log10 copies/mL) decreased at a similar rate from baseline to study day 7 [motavizumab 30 mg/kg: 8.35 (2.5-9.5) to 5.03 (2.5-6.8); motavizumab 100 mg/kg: 8.22 (5.5-9.7) to 4.25 (2.5-8.0); placebo: 8.02 (6.7-9.8) to 5.17 (2.5-7.3)]. Median (range) duration of hospitalization was 3.05 (0.8-16.0), 2.99 (1.0-25.0) and 2.88 (0.8-11.7) days for the motavizumab 30 mg/kg, motavizumab 100 mg/kg and placebo groups, respectively. Six (8%) motavizumab and 0 placeborecipients were admitted to the intensive care unit and 4 required mechanical ventilation. The incidence of wheezing episodes during the 12-month follow up was comparable for all 3 groups. CONCLUSIONS:Motavizumab had no appreciable effect on RSV viral load measured in the upper respiratory tract of children hospitalized for RSV lower respiratory tract infection. No differences were observed for duration of hospitalization, severity of illness measures or wheezing episodes during 12-month follow up in children treated with motavizumab or placebo.
RCT Entities:
BACKGROUND: This study was conducted to determine whether treatment with motavizumab, an anti-respiratory syncytial virus (RSV) monoclonal antibody, would decrease viral load and improve clinical outcomes in previously healthy term infants hospitalized with RSV lower respiratory tract infection. METHODS:Infants hospitalized with lower respiratory tract infection and a positive RSV test performed locally were randomized to receive 1 intravenous dose of motavizumab (30 or 100 mg/kg) or placebo. Nasal wash samples were tested by real-time reverse transcriptase polymerase chain reaction at a central laboratory to determine viral load. Clinical data were collected during RSV hospitalization and at 12-month follow up. RESULTS: Of 118 infants, 112 were confirmed RSV positive by real-time reverse transcriptase polymerase chain reaction. In each study group, median (range) RSV load (log10 copies/mL) decreased at a similar rate from baseline to study day 7 [motavizumab 30 mg/kg: 8.35 (2.5-9.5) to 5.03 (2.5-6.8); motavizumab 100 mg/kg: 8.22 (5.5-9.7) to 4.25 (2.5-8.0); placebo: 8.02 (6.7-9.8) to 5.17 (2.5-7.3)]. Median (range) duration of hospitalization was 3.05 (0.8-16.0), 2.99 (1.0-25.0) and 2.88 (0.8-11.7) days for the motavizumab 30 mg/kg, motavizumab 100 mg/kg and placebo groups, respectively. Six (8%) motavizumab and 0 placebo recipients were admitted to the intensive care unit and 4 required mechanical ventilation. The incidence of wheezing episodes during the 12-month follow up was comparable for all 3 groups. CONCLUSIONS:Motavizumab had no appreciable effect on RSV viral load measured in the upper respiratory tract of children hospitalized for RSV lower respiratory tract infection. No differences were observed for duration of hospitalization, severity of illness measures or wheezing episodes during 12-month follow up in children treated with motavizumab or placebo.
Authors: Jordan R Willis; Gopal Sapparapu; Sasha Murrell; Jean-Philippe Julien; Vidisha Singh; Hannah G King; Yan Xia; Jennifer A Pickens; Celia C LaBranche; James C Slaughter; David C Montefiori; Ian A Wilson; Jens Meiler; James E Crowe Journal: J Clin Invest Date: 2015-05-18 Impact factor: 14.808
Authors: Seyhan Boyoglu-Barnum; Sean O Todd; Tatiana Chirkova; Thomas R Barnum; Kelsey A Gaston; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson Journal: Virology Date: 2015-05-15 Impact factor: 3.616
Authors: Alexey Ruzin; Olivier Barraud; Li Yu; Bruno François; Miguel Sánchez-Garcia; Philippe Eggimann; Pierre-François Dequin; Pierre-François Laterre; Vincent Huberlant; Lucia Viña; Thierry Boulain; Cedric Bretonniere; Jérôme Pugin; José Trenado; Ana Catalina Hernandez Padilla; Julie Vignaud; Drieke Vandamme; Herman Goossens; Christine Lammens; S Omar Ali; Kathryn Shoemaker; Pin Ren; Susan Colbert; Terramika Bellamy; Bret R Sellman; Michael McCarthy; Hasan S Jafri; Mark T Esser Journal: J Clin Microbiol Date: 2022-06-27 Impact factor: 11.677
Authors: Edward E Walsh; Lu Wang; Ann R Falsey; Xing Qiu; Anthony Corbett; Jeanne Holden-Wiltse; Thomas J Mariani; David J Topham; Mary T Caserta Journal: J Infect Dis Date: 2018-06-20 Impact factor: 5.226
Authors: Larry Zeitlin; Kevin J Whaley; Gene G Olinger; Michael Jacobs; Robin Gopal; Xiangguo Qiu; Gary P Kobinger Journal: Curr Opin Virol Date: 2016-01-27 Impact factor: 7.090